AbbVie Reports Positive TRANSFORM-1 Trial Results for Navitoclax in Myelofibrosis

AbbVie today announced positive results from the Phase 3 TRANSFORM-1 trial evaluating navitoclax in combination with ruxolitinib in patients with myelofibrosis who are JAK inhibitor-naive. The trial met its primary endpoint, demonstrating a significantly higher rate of spleen volume reduction of 35% or more at week 24 compared to placebo plus ruxolitinib.